Last update Aug. 29, 2021

1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate)

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Phytic acid and its salts, phytates, are phosphorous compounds that are widely distributed in vegetables, especially in cereal, oilseed and legume seeds (Martínez 2002).

Low doses have been attributed therapeutic properties, not well demonstrated, in the prevention of cancer, kidney stone formation and cardiovascular diseases (Chatree 2020, Torrecilla 2020, Garcia 2019, Fakier 2019, Robertson 2017, Curhan 2004, Martínez 2002).

At the date of the last update, there was no available published data on its excretion in breast milk.

Phytates are chelators, that is, they form insoluble compounds with some minerals, such as calcium, iron, copper and zinc, and proteins, making their intestinal absorption difficult. An excess of phytates in the diet can cause a deficit of these minerals in diets poor in minerals (Lawrence 2016 p310, Martinez 2002, Moser 1988).
The daily needs of Zn depend on the daily intake of phytates. In lactating mothers they are 11 mg for low intakes of phytates (≤ 330 mg/day) and 14 mg/day for high intakes (≥ 990 mg/day) of phytates (Haase 2020).

A balanced diet ensures an adequate intake of phytates. With the usual diet, the daily intake of phytates is 300 to 900 mg/day in Western diets, more than 1,000 mg/day in vegetarian diets, and more than 2,000 mg/day in certain African populations (Schlemmer 2009).

Vegetarian diets are very rich in phytates. Vegetarian lactating mothers should avoid excess phytates and bran (Lawrence 2016 p310).

With a varied diet, phytate supplements are not required.

Other dietary treatments to prevent kidney stone formation include reducing meat consumption and increasing vegetables and calcium in the diet (Heilberg 2013, Curhan 2004).


See below the information of these related products:

  • Vegetarian Diets (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Zinc (systemic administration) (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) is Fytate; Phytate in Chemical name.

Is written in other languages:

1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) is also known as

Group

1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) belongs to this group or family:

Tradenames

Main tradenames from several countries containing 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition:

  • Broken™. Contains other elements than 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition
  • Citrafitina™. Contains other elements than 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition
  • Fyton
  • Lightening™. Contains other elements than 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition
  • Metiofitina™. Contains other elements than 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition
  • Phytic Acid™. Contains other elements than 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition
  • Quadevit (Квадевит)™. Contains other elements than 1,2,3,4,5,6-Cyclohexanehexolphosphoric acid; Myo-inositolhexakis(dihydrogen phosphate) in its composition

Pharmacokinetics

Variable Value Unit
Molecular weight 660 - 858 daltons
pKa 0.14 -

References

  1. Chatree S, Thongmaen N, Tantivejkul K, Sitticharoon C, Vucenik I. Role of Inositols and Inositol Phosphates in Energy Metabolism. Molecules. 2020 Nov 1;25(21). pii: E5079. Abstract
  2. Torrecilla C, Fernández-Concha J, Cansino JR, Mainez JA, Amón JH, Costas S, Angerri O, Emiliani E, Arrabal Martín MA, Arrabal Polo MA, García A, Reina MC, Sánchez JF, Budía A, Pérez-Fentes D, Grases F, Costa-Bauzá A, Cuñé J. Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial. BMC Urol. 2020 Jun 5;20(1):65. Abstract
  3. Haase H, Ellinger S, Linseisen J, Neuhäuser-Berthold M, Richter M; German Nutrition Society (DGE).. Revised D-A-CH-reference values for the intake of zinc. J Trace Elem Med Biol. 2020 Apr 23;61:126536. Abstract Full text (link to original source)
  4. Fakier S, Rodgers A, Jackson G. Potential thermodynamic and kinetic roles of phytate as an inhibitor of kidney stone formation: theoretical modelling and crystallization experiments. Urolithiasis. 2019 Dec;47(6):493-502. Abstract
  5. García Nieto VM, Luis Yanes MI, Tejera Carreño P, Perez Suarez G, Moraleda Mesa T. The idiopathic hypercalciuria reviewed. Metabolic abnormality or disease? Nefrologia. 2019 Nov - Dec;39(6):592-602. Abstract
  6. Robertson WG. Do "inhibitors of crystallisation" play any role in the prevention of kidney stones? A critique. Urolithiasis. 2017 Feb;45(1):43-56. Abstract
  7. Lawrence RA, Lawrence RM. Breastfeeding. A guide for the medical profession. Eighth Edition. Philadelphia: Elsevier; 2016
  8. Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis. 2013 Mar;20(2):165-74. Abstract
  9. Schlemmer U, Frølich W, Prieto RM, Grases F. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res. 2009 Sep;53 Suppl 2:S330-75. Abstract
  10. Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med. 2004 Apr 26;164(8):885-91. Abstract
  11. Martínez Domínguez B, Ibáñez Gómez MV, Rincón León F. [Phytic acid: nutritional aspects and analytical implications]. Arch Latinoam Nutr. 2002 Sep;52(3):219-31. Review. Spanish. Abstract
  12. Moser PB, Reynolds RD, Acharya S, Howard MP, Andon MB, Lewis SA. Copper, iron, zinc, and selenium dietary intake and status of Nepalese lactating women and their breast-fed infants. Am J Clin Nutr. 1988 Apr;47(4):729-34. Abstract

Total visits

1,798

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM